폐암 진단 검사 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global lung cancer diagnostic tests market size is expected to reach USD 32.44 Billion in 2034 from USD 16.00 Billion in 2025, growing at a CAGR of 8.17% during 2026-2034.This market is expanding as healthcare systems increasingly emphasize early lung cancer detection, accurate disease classification, and timely treatment planning. Diagnostic testing for lung cancer includes imaging procedures, tissue biopsies, molecular testing, and other methods used to identify and characterize suspicious lung lesions. Growing awareness of lung cancer risk factors, expanding access to diagnostic services, and improvements in medical imaging are supporting demand. Low-dose computed tomography screening is also important for eligible high-risk populations in settings where screening programs are available. These developments are encouraging healthcare providers to strengthen diagnostic pathways and improve coordination between screening and specialist care.

Market growth is driven by advances in molecular diagnostics, increasing use of imaging technologies, and growing demand for personalized oncology. Diagnostic laboratories are expanding their capabilities to identify genetic alterations and biomarkers that can help guide targeted treatment decisions. Artificial intelligence-assisted imaging tools are being developed to support image interpretation and identify suspicious findings, although clinical validation remains important. Improvements in minimally invasive biopsy techniques and molecular testing are also helping clinicians obtain information about tumors. In addition, investments in cancer research and expanded access to specialized respiratory and oncology services are supporting the development of diagnostic capabilities.

The future prospects of this market will be shaped by advances in early detection, liquid biopsy, molecular profiling, and AI-assisted imaging. Blood-based testing approaches may help researchers develop less invasive methods for identifying disease-related signals, although their clinical roles depend on supporting evidence and regulatory approval. Greater integration of imaging, pathology, and genomic data could help healthcare professionals make more informed diagnostic and treatment decisions. However, false-positive findings, diagnostic costs, unequal access to screening, and the need for confirmatory testing remain important challenges. Continued clinical research and improvements in diagnostic infrastructure will be essential for supporting reliable and timely lung cancer diagnosis.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Cancer Type

• Non-Small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer (SCLC)

By Test Type

• Imaging Tests
• Sputum Cytology
• Biopsy
• Molecular Tests
• Other Tests

By End User

• Hospitals
• Specialty Clinics
• Other Facilities

COMPANIES PROFILED

• Roche, Abbott, Thermo Fisher Scientific, QIAGEN, Foundation Medicine, Guardant Health, Exact Sciences, Biodesix, Veracyte, NeoGenomics, Burning Rock Biotech, Amoy Diagnostics, Bio-Rad Laboratories, Agilent Technologies, Illumina, Natera, Geneseeq, Singlera Genomics, Guardant, Personalis

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL LUNG CANCER DIAGNOSTIC TESTS MARKET: BY CANCER TYPE 2022-2034 (USD MN and Units)

• 4.1. Market Analysis, Insights and Forecast Cancer Type
• 4.2. Non-Small Cell Lung Cancer (NSCLC) Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 4.3. Small Cell Lung Cancer (SCLC) Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)

Chapter 5. GLOBAL LUNG CANCER DIAGNOSTIC TESTS MARKET: BY TEST TYPE 2022-2034 (USD MN and Units)

• 5.1. Market Analysis, Insights and Forecast Test Type
• 5.2. Imaging Tests Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 5.3. Sputum Cytology Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 5.4. Biopsy Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 5.5. Molecular Tests Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 5.6. Other Tests Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)

Chapter 6. GLOBAL LUNG CANCER DIAGNOSTIC TESTS MARKET: BY END USER 2022-2034 (USD MN and Units)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 6.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 6.4. Other Facilities Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)

Chapter 7. GLOBAL LUNG CANCER DIAGNOSTIC TESTS MARKET: BY REGION 2022-2034 (USD MN and Units)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
  • 7.2.1 By Cancer Type
  • 7.2.2 By Test Type
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
  • 7.3.1 By Cancer Type
  • 7.3.2 By Test Type
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Spain
  • 7.3.9 Russia
  • 7.3.10 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
  • 7.4.1 By Cancer Type
  • 7.4.2 By Test Type
  • 7.4.3 By End User
  • 7.4.4 China
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 India
  • 7.4.8 Australia
  • 7.4.9 South East Asia
  • 7.4.10 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
  • 7.5.1 By Cancer Type
  • 7.5.2 By Test Type
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
  • 7.6.1 By Cancer Type
  • 7.6.2 By Test Type
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL LUNG CANCER DIAGNOSTIC TESTS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Roche
  • 9.2.2 Abbott
  • 9.2.3 Thermo Fisher Scientific
  • 9.2.4 QIAGEN
  • 9.2.5 Foundation Medicine
  • 9.2.6 Guardant Health
  • 9.2.7 Exact Sciences
  • 9.2.8 Biodesix
  • 9.2.9 Veracyte
  • 9.2.10 NeoGenomics
  • 9.2.11 Burning Rock Biotech
  • 9.2.12 Amoy Diagnostics
  • 9.2.13 Bio-Rad Laboratories
  • 9.2.14 Agilent Technologies
  • 9.2.15 Illumina
  • 9.2.16 Natera
  • 9.2.17 Geneseeq
  • 9.2.18 Singlera Genomics
  • 9.2.19 Guardant
  • 9.2.20 Personalis